Cargando…

Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study

BACKGROUND: Anti-programmed cell death protein-1 immunotherapy has been approved as a new treatment option for advanced hepatocellular carcinoma (HCC) based on the promising results of several studies. METHODS: This retrospective study included 71 patients with advanced HCC treated with anti-program...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mei, Zhang, Yiruo, Wang, Hua, Liu, Pingping, Da, Jie, Du, Yingying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Current Technologies in Targeted Cancer Immunotherapies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450682/ https://www.ncbi.nlm.nih.gov/pubmed/34525851 http://dx.doi.org/10.1177/15330338211038114

Ejemplares similares

CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers
por: Zhang, Hongpan, et al.
Publicado: (2021)

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes
por: Tatovic, D, et al.
Publicado: (2022)

CpG Oligodeoxynucleotide Promotes Apoptosis of Human Bladder Cancer T24 Cells Via Inhibition of the Antiapoptotic Factors
por: Luo, Yang, et al.
Publicado: (2019)

A Machine Learning Algorithm for Predicting Therapeutic Response to Anti-PD1
por: Yan, Yuanliang, et al.
Publicado: (2019)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Global research trends on immunotherapy in cancer: A bibliometric analysis
por: Yao, Zhichao, et al.
Publicado: (2023)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
por: Pinato, David J., et al.
Publicado: (2021)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects
por: Urooj, Tabinda, et al.
Publicado: (2020)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
por: DeBenedette, Mark, et al.
Publicado: (2023)

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
por: Burnell, Stephanie E A, et al.
Publicado: (2021)

Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors
por: de Britto Evangelista, Guilherme Ferreira, et al.
Publicado: (2022)

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
por: Rossetti, Rafaela, et al.
Publicado: (2022)

Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity
por: Silla, Lucia
Publicado: (2023)

Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases
por: Minniti, Giuseppe, et al.
Publicado: (2021)

Advances in immunotherapy for cervical cancer
por: Grau-Bejar, Juan Francisco, et al.
Publicado: (2023)

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials
por: Eskander, Ramez N., et al.
Publicado: (2021)

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
por: Deng, Jia-Yi, et al.
Publicado: (2023)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Melanoma stem cell vaccine induces effective tumor immunity against melanoma
por: Yin, Qiliang, et al.
Publicado: (2023)

Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects
por: Wang, Yu, et al.
Publicado: (2023)

Profile EpicentRx, Inc
por: Oronsky, Bryan
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q775k8o49lhdnpd0hfmuam3l94